Activation of the viral sensor oligoadenylate synthetase 2 (Oas2) prevents pregnancy-driven mammary cancer metastases

Wing-Hong Jonathan Ho

Garvan Institute of Medical Research

Andrew M. K. Law

Garvan Institute of Medical Research

Etienne Masle-Farquhar

Garvan Institute of Medical Research

Lesley E. Castillo

Garvan Institute of Medical Research

Amanda Mawson

Garvan Institute of Medical Research

Moira K. O'Bryan

The University of Melbourne School of BioSciences

Christopher C. Goodnow

Garvan Institute of Medical Research

David Gallego Ortega

University of Technology Sydney

Samantha R. Oakes

National Breast Cancer Foundation

Christopher Ormandy (✉ c.ormandy@garvan.org.au)

Garvan Institute of Medical Research <https://orcid.org/0000-0002-2504-7919>

Research article

Keywords: OAS2, interferon, immunotherapy, breast, mammary, cancer

Posted Date: September 2nd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-842107/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Activation of the viral sensor oligoadenylate synthetase 2 (*Oas2*) prevents pregnancy-driven mammary cancer metastases.

Wing-Hong Jonathan Ho¹, Andrew M. K. Law¹, Etienne Masle-Farquhar¹, Lesley E. Castillo¹, Amanda Mawson¹, Moira K. O'Bryan², Christopher C. Goodnow¹, David Gallego-Ortega^{1,3}, Samantha R. Oakes^{1,4,5} and Christopher J. Ormandy^{1,4,6}

¹ Garvan Institute of Medical Research, 384 Victoria Street Darlinghurst Sydney, NSW, 2010, Australia, and St. Vincent's Clinical School, St. Vincent's Hospital, UNSW Sydney, Australia.

² The School of BioSciences and Bio21 Institute, Faculty of Science, The University of Melbourne, Parkville, Melbourne, Vic. 3010, Australia.

³ Current address, School of Biomedical Engineering, Faculty of Engineering and Information Technology, University of Technology Sydney, 81 Broadway, Ultimo Sydney, NSW, 2007, Australia.

⁴ Joint senior authors.

⁵ Current address, National Breast Cancer Foundation, 9/10 Barrack Street, Sydney NSW, 2000, Australia.

⁶ To whom correspondence should be addressed.

Running title; OAS2 activation prevents metastases.

Keywords; OAS2, interferon, immunotherapy, breast, mammary, cancer.

Wing-Hong Jonathan Ho j.ho@garvan.org.au

Andrew Law a.law@garvan.org.au

Etienne Masle-Farquhar e.masle-farquhar@garvan.org.au <https://orcid.org/0000-0001-9355-8027>

Lesley Castillo CastilloLesley@prahs.com

Amanda Mawson a.mawson@garvan.org.au

Moira K. O'Bryan moira.obryan@unimelb.edu.au <http://orcid.org/0000-0001-7298-4940>

Christopher C. Goodnow c.goodnow@garvan.org.au <http://orcid.org/0000-0001-5296-6155>

David Gallego Ortega David.GallegoOrtega@uts.edu.au <https://orcid.org/0000-0002-2347-7835>

Samantha R. Oakes samantha.oakes@nbcf.org.au <https://orcid.org/0000-0003-1838-2310>

Christopher J. Ormandy c.ormandy@garvan.org.au <https://orcid.org/0000-0002-2504-7919>

Abstract

Background. The interferon response can influence the primary and metastatic activity of breast cancers and can interact with checkpoint immunotherapy to modulate its effects. Using N-ethyl-N-nitrosourea mutagenesis we found a mouse with an activating mutation in oligoadenylate synthetase 2 (*Oas2*), a sensor of viral double stranded RNA, that resulted in an interferon response and prevented lactation in otherwise healthy mice.

Methods. To determine if activation of *Oas2* could alter the course of mammary cancer we combined the *Oas2* mutation with the *MMTV-PyMT* oncogene model of breast cancer and examined disease progression and the effects of checkpoint immunotherapy using Kaplan-Meier survival analysis with immunohistochemistry and flow cytometry.

Results. *Oas2* mutation prevented pregnancy from increasing metastases to lung. Checkpoint immunotherapy with antibodies against programmed death-ligand 1 (PD-L1) was more effective when the *Oas2* mutation was present.

Conclusions. These data establish OAS2 as a therapeutic target for agents designed to reduce metastases and increase the effectiveness of checkpoint immunotherapy in cases of pregnancy-associated breast cancer and outside of pregnancy in cases showing the lactation and involution-mimicry phenotypes.

Background.

The interferon response can influence the primary and metastatic activity of breast cancers ¹, and can interact with checkpoint immunotherapy to modulate its effects ². Although systemic interferon delivery for cancer produced responses in tumors, it was limited by severe adverse events and has been superseded by newer therapies ³. To circumvent some of these challenges intratumor injection of agents that induce an interferon response are currently being trialled in a large number of cancer settings and among these agents are derivatives of polyinosinic–polycytidylic acid (polyIC) ⁴. In mice polyIC greatly improved the ability of anti PD-L1 therapy to clear or reduce melanomas and cancers of the lung and colon, and this effect was dependent on type 1 interferons ⁵.

PolyIC mimics viral double-stranded RNA and activates a diverse range of pathogen recognition receptors including the oligoadenylate synthetase (OAS) family, retinoic acid induced gene 1 (RIG1)-like family and toll-like receptors. The OAS family of proteins are often overlooked as potent inducers of the interferon response. They are pathogen recognition receptors that bind double-stranded RNA in the cytoplasm, a key pathogen-associated molecular-pattern that is displayed during viral replication ⁶. These proteins respond by synthesizing 2'-5'-linked RNA from ATP without a template ⁷. This in turn binds to and activates latent ribonuclease (RNaseL), causing it to degrade viral RNA and host ribosomal RNA, so disrupting the viral life cycle. Activation of OAS-RNaseL also promotes apoptosis and provokes a robust interferon response, both via poorly understood mechanisms that involve additional detection of RNaseL-degraded RNA by the RIG1-like pathogen recognition receptors and interaction with the mitochondria ⁸.

Activation of OAS2-RNaseL was predicted to alter outcomes in virally-induced cancers, and an association with RNaseL allelic variation and the risk of human papilloma virus-driven cancers of the cervix and head was demonstrated. Unexpectedly this study also found an association with cancers that do not show a strong viral etiology such as breast ⁹. Activation of OAS-RNaseL may occur naturally in cancers, driven by the recognition of double-stranded RNA species produced from viral sequences integrated in the genome. These sequences are usually silenced by methylation but are transcribed *de novo* as a result of the general demethylation of the genome that occurs in cancer cells. This was demonstrated by the finding that cells deficient in the OAS-

RNaseL pathway were highly resistant to the cytotoxicity of 5-azacytidine, a drug that demethylates the genome. Cells were made resistant to 5-azacytidine via inhibition of RNaseL¹⁰.

Other cancer studies found that allelic variation in RNaseL was observed to be associated with increased risk of prostate cancer and the increased risk of higher tumor grade, together with an increased level of inflammation markers^{11, 12}. Allelic variation of RNaseL may modify the risk of breast cancer in patients carrying high risk mutations¹³. The inherited RNaseL alleles responsible for this are proposed to reduce RNaseL activity, and this proposition is supported by observations in lung cancer cells, which increased the levels of the RNaseL inhibitor RL1 to suppress RNaseL-driven apoptosis, with mitochondrial-mediated apoptosis restored by interferon gamma¹⁴.

Our laboratories conducted an N-ethyl-N-nitrosourea mutagenesis project in mice to find new genes driving mammary gland development and function, with the intent of also identifying new genes involved in mammary cancer initiation and metastasis. We discovered a dominant mutation in *Oas2*, (referred to as MT, wild type *Oas2* referred to as WT) causing a non-conservative amino acid change that resulted in failed lactation despite normal mammary development during pregnancy. These mice were otherwise completely normal¹⁵. We observed a robust interferon response associated with apoptosis in the mammary glands of our MT mice. When MT was expressed in human breast cancer cells we found that the interferon response depended on the presence of RNaseL and interferon regulatory factor 7 (IRF7), the key effector molecules at the proximal and distal ends of the OAS-RNaseL signaling pathway¹⁵. This was the first observation of a regulatory pathway linking activation of viral recognition to the control of lactation. The *Oas2* mutant mouse provides a defined and single molecular event that induces an interferon response, with pathological activity only in the mammary gland at the onset of lactation.

To determine if activation of OAS-RNaseL can alter the initiation or progression of mammary cancer, and the interaction with checkpoint immunotherapy, we combined the *Oas2* mutation with expression of the polyoma middle T oncogene (*PyMT*) driven by the mouse mammary tumor virus promoter (*MMTV*)¹⁶. This *MMTV*-*PyMT* model is the most widely used mouse model of breast cancer. PyMT protein¹⁷ acts as a scaffold promoting persistent signaling via binding of SRC family kinases, PI3K, SHC, 14-3-3, PLC-gamma and TAZ. It causes early and multifocal onset of estrogen receptor positive hyperplasia that rapidly progresses through a series of well-

defined lesions to estrogen receptor negative invasive carcinoma of the luminal
molecular subtype¹⁸. The model is weakly sensitive¹⁹ or refractory²⁰ to PD-L1 or PD-
1 as monotherapy. Metastasis to lung is frequent and strongly dependent on innate
immune cells previously characterized, as macrophages^{21, 22} or myeloid derived
suppressor cells (MDSC)²³ of monocytic (G-MDSC) or neutrophil (PMN-MDSC)
origin, and now thought of as pathologically activated monocytes and neutrophils²⁴.

Methods

Mice. The *Oas2* colony ¹⁵, on an inbred FVBN background was crossed with the polyoma middle T antigen mouse (*MMTV-PyMT*) also on an FVBN background, a kind gift from Dr. William Muller ¹⁶. The colony was then maintained by breeding compound heterozygous males (MT *Oas2*/WT *Oas2* / *MMTV-PyMT*/non transgenic) with WT *Oas2*/WT *Oas2* and non-transgenic FVBN females. All animals were housed with food and water ad libitum with a 12-h day/night cycle at 22°C and 80% relative humidity.

Timed Mating. One or two 7-9 weeks old females were housed with single males overnight and monitored daily for a vaginal plug, and pregnancy was confirmed by weight gain. Females were single housed for parturition and pups culled at birth. Mammary gland tumors were measured with callipers throughout pregnancy and the post-partum period. Tumor volume (mm³) was calculated as (minimum measurement²)*(maximum measurement)/2. Mice were euthanized at specified endpoints, via anesthesia (5% isoflurane, 1L/min O₂) followed by cervical dislocation. At autopsy 4th and combined 2nd/3rd glands or tumor weights were recorded.

PDL-1 Antibody Treatment in Parous Mice. Parous mice received 10μl per gram body weight of a solution of PDL-1 (cat BP0101) or IgG control (cat BP0090) at 1mg/ml via I.P. injection for six treatments, delivered twice weekly.

Mammary gland whole mounts and lung collection. Mouse mammary glands, tumors and lungs were harvested at specified timepoints, and fixed in 10% buffered formalin for 4 hours at room temperature. Tissues were changed into 70% ethanol prior to embedding in paraffin. Mammary glands were defatted in 3–4 changes of acetone before being dehydrated and stained in carmine alum for whole mount photography. Glands were then passed through a series of graded alcohols and embedded in paraffin for sectioning and immunohistochemistry.

Immuno-histochemistry. Tissue sections were either stained with hematoxylin and eosin for routine histochemistry or stained with antibodies to the following antigens using immunohistochemistry protocols as detailed in Supplementary Table 1. For analysis of lung metastasis, two or more sections at 100μm intervals were cut for staining.

Image analysis. Whole mammary gland or lung sections on glass slides were scanned in Aperio ScanScope XT at Katharina Gaus Light Microscopy Facility, and Garvan Microscope Facility, Sydney, Australia, and analyzed by QuPath ²⁵. A set of multiple reference images was used to train the DAB pixel detection algorithm. Quantification of phospho-Stat positive nuclei used the positive cell detection QuPath algorithm. Regions contain positive 3,3'-diaminobenzidine (DAB), hematoxylin or no-stain were classified by batch processing and reported as total tissue area (μm²), DAB-stained area (μm²), non-DAB-stained area (μm²) and non-stained area (μm²). DAB stain area percentage without lumen non-stained area was calculated as;

PYMT stain area percentage with non – stained area

$$= \left(\frac{\text{PYMT stain area}}{\text{PYMT stain area} + \text{non – PYMT stain area}} \right) * 100$$

Kaplan–Meier survival analysis, graph drawing and statistical tests were performed in GraphPad Prism 8.0.2. Strong evidence against the observation being made by chance was accepted at the 90% level.

Immune Cell Profiling by Flow Cytometry. Mouse mammary glands (2/3rd & 4th) were crudely macerated and cells disassociated in 1% hyaluronidase, 37°C shaking, 20min. Digestion was neutralized with 2% fetal calf serum (FCS) / phosphate buffered saline (PBS) prior to centrifugation at 1200rpm, 4°C. Cell pellets were resuspended (25μg/ml DNaseI in 2% FCS / PBS) and strained through 40μm mesh and the supernatant concentrated by centrifugation. Cell pellets were resuspended 0.8% NH₄Cl, DNaseI (25μg/ml) in PBS and incubated in 37°C water bath, 1min. Red blood cells (RBC) / DNA lysis was neutralized in 7x volume 2% FCS / PBS prior to centrifugation and resuspension in 2% FCS / PBS for immune cell staining using fluorophore conjugated antibodies (refer to antibody panels in Supplementary Table 2). Mouse spleen, thymus and lymph nodes (from 4th mammary glands) were collected separately into RPMI media (+10% FCS) and strained through 70μm mesh directly prior to RBC / DNA lysis, cell resuspension and immune cell staining steps (as detailed above). Flow cytometry was performed using BD LSR II SORP and data exported to the FlowJo software (Tree Star Inc.) for data analysis. Routine T ^{26, 27} and innate immune cell protocols ²⁸ were followed using antibodies listed in Supplementary Table 2.

Results.

Effects of pregnancy and mutation of *Oas2* in the *MMTV-PyMT* model.

MMTV-PyMT mice were made pregnant at 7-9 weeks of age and analyzed between days 1-3 post-partum. Tumors arose in all glands and were generally first detected by palpation in the combined 2nd and 3rd glands. *MMTV-PyMT* mice showed normal mammary ductal elongation and branching (Fig. 1A), with alveolar bud formation, but failed lobuloalveoli development (FLAD) during pregnancy. At the end of pregnancy lobuloalveoli would normally completely fill the fat pad and very few adipocytes would be seen, but in *MMTV-PyMT* glands this does not occur. As a result there were no observable differences in mammary gland development between parous MT and WT mice. The failure of *MMTV-PyMT* dams to feed their pups has been noted previously ¹⁶. This is due to a developmental defect and not physical obstruction of the ductal network as often assumed. The mammary ductal tree showed the same characteristic early lesions identified by Lin et al. ¹⁸, hyperplasia, adenoma/MIN, and early carcinoma, with late carcinoma dominant at animals that reached the ethical endpoint. These lesions were arranged in a gradient from youngest to oldest epithelium, hyperplasia to carcinoma, left to right in Fig. 1A. IHC showed that PyMT levels were lowest in hyperplasia and highest in adenoma/MIN (Fig. 1B). We observed no histopathological differences between MT and WT mice. Two novel features were observed in parous mice due to the accumulation of milk within the gland (Fig. 1C). In some mice engorgement with milk of adenoma/MIN produced highly distended ducts, seen on the left-hand side of the combined 2nd and 3rd mammary gland shown in Fig. 1B, which stained strongly for milk-associated protein (MAP). A second feature we have called engorged carcinoma was characterized as misshapen and fluid-filled lumina, formed by a much-thickened fibrous basement membrane containing fibroblasts and immune cells. Epithelial cells accumulated in multiple layers within the lumina. MAP staining was present but weak, suggesting production of the major milk osmoticon lactose, but relative suppression of milk protein synthesis. Areas of early carcinoma and late carcinoma formed within fields of engorged carcinoma, distinguished by the loss of lumina, poorly defined pseudo-alveoli and milk staining limited to developing necrotic areas. Lung metastases showed a uniform pseudo-alveolar pattern typical of the early carcinoma stage. These lesions expanded and developed necrotic centres, but the pseudo-alveolar pattern never varied (Fig. 1D). The

metastasis stained strongly for MAP which accumulated within the pseudo-alveoli and in the interstitial spaces (Fig.1E). Single PyMT positive cells were never seen, the smallest lesions presented as pseudo-alveoli formed from as few as 4 cells, suggesting that metastasis may occur as groups of mammary epithelial cells.

Adenoma/MINs and carcinomas were not engorged with milk at day 15 post-partum or at later times, demonstrating that these features regress dramatically in volume immediately post-partum by reabsorption of the engorging-secretions. This is probably responsible for the regressions in tumor volume that we observed by palpation during the post-partum period (SFig1). Tumor regressions and periods of no tumor expansion occurred in 42% and 42% of mutant MT mice respectively, compared to 21% and 26% of WT mice respectively. This is consistent with the complete failure of lactation in MT mice ¹⁵ and thus faster loss of these engorged features.

We previously reported that the *Oas2* mutation caused disruption of Signal Transducer And Activator Of Transcription (Stat) phosphorylation ¹⁵ and we determined if this also occurred when combined with the *MMTV-PyMT* oncogene in the immediate post-partum period, when OAS2 levels are highest having been induced through pregnancy ¹⁵ (Fig. 2A). Phosphorylated Stat1 (pStat1) was seen as small foci of DAB+ nuclei in all stages of tumor progression and quantification using QuPath ²⁵ suggested that some MT animals expressed higher pStat1, as reported in non *PyMT* animals ¹⁵. Phosphorylated Stat3 (pStat3) was expressed at lower frequency in carcinoma epithelial cells compared to cells from the other stages and more frequently in MT glands. Phosphorylated Stat5 (pStat5) was more frequently expressed in hyperplasia and showed a reduction in the frequency of expression as the disease progressed to carcinoma, correlating with milk protein levels. pStat5 was less frequently expressed in MT glands, as previously reported for non *PyMT* animals ¹⁵. Thus, the effects of MT on Stat activation continue in *PyMT* animals.

We previously reported increased mammary epithelial cell apoptosis in response to MT in non-PyMT mice following parturition ¹⁵. We used staining for cleaved caspase 3 (CC3) to look for this effect in mice also carrying the *PyMT* oncogene (Fig. 2B). We found no effect when whole glands were analysed without regard to lesion type prompting an analysis within lesion types. The highest rates of apoptosis were seen in engorged MIN compared to the other lesion types. There were no significant differences in apoptosis between MT and WT animals in any of the lesion

types. This suggests that transformation with PyMT abrogates the apoptotic effects of OAS2 activation.

Effects of MT OAS2 on tumor progression and metastasis.

Cohorts of 20 WT or MT *PyMT Oas2* mice were kept nulliparous or were made pregnant (80 mice total) from 7-9 weeks of age and all pups were removed at birth. Mice were monitored by mammary palpation at twice-weekly intervals. Tumor onset and growth was measured in the major and minor axes using callipers, and mice were euthanized at the estimated ethical endpoint of 10% tumor burden prior to autopsy. Animal survival to various endpoints was analyzed using Kaplan-Meier survival plots with log-rank p values and hazard ratios calculated by the Cox proportional hazards model as implemented in GraphPad-Prism (Fig. 3, and SFig. 2 for p values and hazard ratios (HR) of two-way comparisons).

Survival to the age of initial tumor detection (Fig. 3A), showed that tumors in WT parous animals were detected at a younger age than WT nulliparous animals, 66 compared to 78 days ($p=0.0038$). MT parous animals also had tumors detected at a younger age than MT nulliparous animals, 65.6 days compared to 77.5 days ($p=0.0019$). There was no difference in the age of tumor detection between WT and MT animals, either parous or nulliparous. The period from tumor detection to ethical endpoint (Fig. 3B) was not different among WT nulliparous, WT parous or MT parous animals. MT nulliparous animals progressed more quickly than those in the other cohorts, 22.5 days compared to 31 days ($p=0.002$) for WT parous, 35 days ($p<0.0001$) for MT parous, and 25.5 days ($p=0.03$) for WT nulliparous. The age that animals reached their ethical endpoint (Fig. 3C) was not different among WT parous, MT parous and MT nulliparous animals. WT nulliparous reached their ethical endpoint later by 5 days ($p=0.0345$), 3 days ($p=0.034$) and 4 days ($p=0.18$) respectively. Overall, parity caused earlier tumor detection but slower tumour progression, opposing effects with the result that parous animals, either MT or WT, reached the ethical endpoint a few days earlier than nulliparous WT animals. The *Oas2* mutation had no effect on the age of tumor detection but caused more rapid progression in nulliparous animals, so that MT nulliparous animals reached the ethical endpoint earlier than nulliparous WT, and at the same age as parous animals. These effects showed HR between 1.8 to 2.9 indicating a two- to three-fold increase in risk.

We examined metastatic burden in two sections of both lungs per mouse from the cohort of mice above, using PyMT IHC to detect metastases and allow measurement of their stained area using QuPath²⁵. In the cohorts there was no difference in tumor burden at the ethical endpoint, measured at autopsy by weighing tumors and body weights (BW) from animals euthanized at an estimated 10% tumor burden by tumor dimensions (Fig. 4A, each symbol is a mouse).

Results for the quantification of metastases are plotted on a log scale due to the skewed and thus non-Gaussian distribution of this data, $p < 0.001$ K2 33-70 using the D'Agostino&Pearson normality test (Fig. 4B). Sections with no lung metastases are indicated as "0" at the bottom of the figure as they can't be plotted on a log axis. Error bars show standard error of the mean, but median values (dashed lines) and the Mann-Whitney nonparametric test of significance are used for comparisons.

Pregnancy caused an increase in the proportion of WT mice with metastases, up from 9 of 19 nulliparous WT mice to 15 of 19 parous WT mice ($p = 0.09$ Fisher's exact test). In contrast, pregnancy made no difference to the number of MT *Oas2* mice with a metastasis, 10 of 20 nulliparous MT mice compared to 8 of 18 parous MT mice ($p = 0.8$ Fisher's exact test). There were half the number of MT mice with metastases than WT mice ($p = 0.04$ Fisher's exact test).

The median number of metastases per lung section (Fig. 4B top panel) rose from 0 in nulliparous WT or MT mice to 6.5 in parous WT mice ($p < 0.0001$ Mann Whitney), but to just 1 in parous MT mice ($p = 0.0016$). Parous MT mice had 6.5 fold fewer metastases than WT mice ($p = 0.0124$). Image analysis was used to quantify the area of lung-metastases as a proportion of lung tissue area (Fig. 4B lower panel). The area of lung alveolar space was excluded from the analysis as individual sections showed variation in the degree of lung inflation at fixation. Parity caused the median area of metastasis in WT lung tissue to increase from 0 to 1.3%, but to just 0.18% in MT animals, a 7-fold decrease in metastases area ($p = 0.0338$). We conclude that activation of OAS2 prevented pregnancy from driving metastases to the lung.

Effects of the OAS2 mutation on the immune system.

Lung metastasis in the *MMTV-PyMT* model is highly dependent on innate immune cells^{18, 21-23} of monocyte and neutrophil origin which are recruited to tumors where they adopt a pathogenic inflammatory and immunosuppressive state capable of modulating T-cell activity, often called MDSC of granulocyte or polymorphonucleated

neutrophil origin (G- or PMN-MDSC), or monocyte origin (M-MDSC). The development of cell surface markers enabling clear distinction of cells that have assumed the pathogenic state remains the key challenge of this field, and the definition of the pathogenic state is currently limited to functional tests²⁴.

We undertook a flowcytometric survey of monocytes and granulocytes in tumors (Fig. 5, gating strategy SFig. 4). Monocyte and neutrophil levels showed individual variation, however, we found a rise in the number of monocytes and neutrophils in more than half of the MT parous tumors compared to WT parous tumors and mean levels increased for both cell types ($p=0.022$ and $p=0.0296$ respectively). Non-oncogene carrying mice showed no significant changes in monocyte levels with MT or parity. Neutrophil levels increased significantly in parous animals compared to nulliparous animals ($p=0.0571$ and $p=0.0043$) but MT was without effect. The presence of a tumor appeared to reduce the ability of parity to increase neutrophil levels in some mice. As monocyte and neutrophil levels increase in the tumors of parous MT mice, but not in all MT mice, these results suggest that any action of MT on monocytes and neutrophils to reduce metastasis must be to prevent the transition of monocytes and neutrophils to the pathogenic state.

To determine if the changes in monocytes and neutrophils altered parameters measured in CD4 and CD8 T cells we surveyed tumors, the draining inguinal lymph node, spleen and thymus. We found great variation among individual mice in most of the measured T-cell parameters, showing that we would require an impractically large cohort size to provide sufficient power to this analysis to detect differences (SFig. 3).

Effects of PD-L1 on tumor progression and metastasis.

To determine if PD-L1 treatment was more effective in parous mice and whether it interacted with MT, we added PD-L1 treatment to the paradigm used above. Mice received either six IgG or PD-L1 treatments (individual details SFig. 4) when tumors first became palpable and generally coinciding with pregnancy and parity. Mice were monitored with twice weekly measurements of major and minor tumor axis to the ethical end point. Data was analyzed by Kaplan Meier survival analysis with log rank p values and Cox proportional hazards estimation of hazard ratios. All tumor growth profiles are shown in in SFig. 4 and all two-way survival comparisons are shown in SFig. 5.

PD-L1 or MT had no effect on the age at which tumors were first detected (Fig 6A, two-way comparisons and p values SFig. 6). PD-L1 treatment slowed tumor progression in MT mice from detection to endpoint, by 10 days compared to IgG treated mice (Fig. 6B), from a median time of 46 to 56 days ($p=0.0036$ HR=3.8). The effect of PD-L1 in MT mice was also apparent at the ethical endpoint (Fig. 6C), where PD-L1 treated MT mice had a median age of 62.5 days compared to MT IgG treated of 67 days ($p=0.065$ HR 1.9). PD-L1 had no effect in WT mice. Tumors in MT IgG treated mice progressed more quickly to the ethical endpoint than in WT mice, and PD-L1 treatment normalized this so that MT PD-L1 treated mice became indistinguishable from WT mice. Since PD-L1 was ineffective in WT mice on tumor progression, we conclude that MT sensitised the mice to PD-L1 treatment, but by promoting more rapid tumor progression which was then ameliorated by PD-L1.

We examined the effect of PD-L1 treatment on metastasis (Fig. 7). Tumor burden was estimated from tumor dimensions and mice were killed at an estimated 10% BW. Actual tumor burden was measured at autopsy. PD-L1 produced slightly lower burden in both WT ($p=0.0813$) and MT mice ($p=0.0939$). In WT animals PD-L1 treatment did not significantly reduce the number of metastases, but in MT animals a significant 7.4-fold reduction occurred from a median of 29.5 to 4 metastases per section ($p=0.001$). The median area of lung-metastases as a proportion of lung tissue area was reduced 9-fold in WT animals from 6.3 to 0.7 ($p=0.002$) and 5-fold in MT animals from 3 to 0.56 ($p=0.0002$). We conclude that MT increased the ability of PD-L1 treatment to reduce metastases seeding to lung.

To determine if PD-L1 was having a greater but transient effect during the treatment period we examined a second cohort of six mice per group immediately after treatment using 2 sections per lung (Fig. 8). Mammary gland weights showed no difference among groups (Fig. 8A). The only group in which any lung sections contained no metastases were MT *Oas2* and PD-L1 treated mice, where half the sections were negative ($p=0.0373$ Fischer's exact test compared to WT PD-L1 treated). The median number of metastases in WT mice increased 2.8-fold from 16.5 to 45.5, but in MT mice it fell 9.2-fold from 23 to 2.5 (Fig 8B upper panel). There was a large difference in median metastasis number per section between WT (45.5) or MT (2.5) animals treated with PD-L1 ($p=0.128$).

Metastases as a percentage of tissue area fell 3.5-fold in WT mice from 3.36% to 0.95% ($p=0.0433$) and 16-fold in MT mice from 4% to 0.25% ($p=0.0001$) (Fig. 8B

lower panel). PD-L1 was more effective in MT Oas2 mice. Interestingly the number of metastases seen two weeks after parity were similar to those detected much later at the ethical endpoint, showing that pregnancy and parity increase metastases within an acute period, rather than over the full length of the post-partum period. These data show that PD-L1 treatment caused a reduction of metastases number and area in MT mice.

In summary, MT prevented the increase in the number and the tissue area of lung metastases caused by parity and MT enhanced the response to PD-L1 therapy.

Discussion

The publications on allelic variation in the Oas-RNaseL pathway suggest that inherited alleles that are thought to cause pathway activation produce better control of virally induced tumors, but also of non-viral tumors by providing an enhanced response to de novo dsRNA production from integrated viruses. A separate group of Oas-RNaseL pathway alleles is thought to cause pathway suppression and to be involved in the genesis of prostate cancer. Our results suggest, however, that the same Oas2 alleles may have context dependant effects. In the nulliparous state activation of Oas2 caused faster primary tumor progression, but in the parous state this effect was lost, and instead suppression of metastases and sensitisation to checkpoint immunotherapy was observed. It is likely that distinct effects of Oas-RNaseL activation within the cells of the epithelium and immune system add complexity to the role of this pathway in cancer.

A fully-completed pregnancy remains an independent predictor of breast cancer risk ²⁹, and pregnancy-associated breast cancer is associated with a 40% increase in mortality due to increased metastasis ²⁹, with even higher rates in cases occurring during pregnancy ³⁰. The period of increased risk caused by pregnancy may last three or more decades for women who have their first child after their mid 30's, but less than a decade for women who have their first child before their early 20's ^{31,32}. A degree of life-long protection then follows. This age-dependent period of increased risk defines a large proportion of breast cancer cases as associated with pregnancy, however, current clinical practice uses arbitrary post-partum time periods to define pregnancy associated breast cancer, and doesn't distinguish pregnancy-associated breast cancer based on the age-dependent period of increased risk. Regardless, this type of breast cancer has no special therapeutic guidelines.

The number of first pregnancies of women over 30 years of age continues to increase especially in developed and developing countries where increasing age at first pregnancy is correlated with increasing female education ^{33,34}. Breast cancer associated with pregnancy ³⁵ is one of the main drivers of the increased prevalence of breast cancer ³⁶. This effect is compounded by an ongoing decrease in breast feeding, as every 12 months decreases breast cancer risk by 4.3%. In developed countries decreases in childbirth and lactation have doubled the cumulative risk of breast cancer, with two thirds of this effect attributable to reduced lactation ³⁷.

The results of this study have direct relevance to the changes in reproduction practices in developed and developing nations. Activation of OAS2 in the *MMTV*-

PyMT model of breast cancer prevented pregnancy from increasing the number of lung metastases, a finding that establishes the OAS family as therapeutic targets for the development of agents designed to prevent pregnancy from driving breast cancer metastasis. A positive interaction with PD-L1 therapy was also detected, providing impetus for further study to determine if the combination of OAS activation and checkpoint inhibition is of therapeutic relevance for the treatment of breast cancer during pregnancy. A cautionary finding was that in nulliparous mice activation of OAS2 resulted in more rapid primary tumor progression, suggesting that in nulliparous women the use of interferon-inducing agents should be carefully examined, especially for local recurrences. As the mechanisms responsible for the effects of pregnancy and lactation on post-partum breast cancer risk are poorly understood these findings may also have significance for our understanding of pregnancy associated breast cancer. Importantly the MT mice show no pathology other than failed lactation, a rare observation in the interferon-response field which is beset with serious adverse events, suggesting that such a therapy would have a favourable toxicity profile.

Our findings may have relevance to breast cancer more generally. We have recently described a pro-metastasis pathology we called involution mimicry³⁸ that occurs in response to forced expression of the ETS transcription factor ELF5, the master regulator of lobuloalveolar development during pregnancy, which causes a limited lactation and ongoing involution response in an ELF5 mouse model²³, but is also seen in breast cancer patients. The ELF5 mouse model shows a similar a engorgement pathology to that we saw following parity in the MT mice and an increase in lung metastasis that is abrogated by neutrophil depletion²³. We found profound changes in the state of the epithelium, cancer associated fibroblasts (CAFs), endothelial cells and immune cells³⁸. Among the CAFs we found populations previously associated with mammary gland involution following lactation, and an analysis of ligand-receptor interactions among these cell types established the existence of a complex regulatory network linking the induction of ELF5 in the epithelium to profound transcriptional changes in the CAFs and endothelial cells, and to the recruitment and M2 polarization of MDSC³⁸. Two linked human molecular signatures were discovered in breast cancer patients, a lactation signature and an involution signature. The lactation signature was enriched in the epithelial cell populations and the involution signature was present in both epithelial and stromal populations. The involution signature was prognostic in the

METABRIC cohort ³⁸. We surmise that elevated ELF5, possibly due to loss of promoter demethylation ³⁹, drives a limited lactation and involution in these breast cancers.

Conclusion

Our results raise the possibility that the use of an OAS family activator, or less specific inducers of the interferon response, could reduce the pro-metastases pathology that occurs in a significant number of breast cancers during pregnancy, the immediate post-partum period and in cases expressing the involution-mimicry phenotype, and that efficacy could be increased by combination with checkpoint immunotherapy. While the magnitude of some of the effects detailed here are modest, that they occur indicates the existence of mechanistic links that may be exploited by new therapeutic strategies.

489 **List of abbreviations**

490

BW	Body weight
CAFs	Cancer associated fibroblasts
CAR	Carcinoma
CC3	Cleaved Caspase 3
DAB	3,3'-diaminobenzidine
ELF5	E-74 like factor 5
ENG	Engorged
ENU	N-ethyl-N-nitrosourea
ETS	E-26 transformation specific
FCS	Fetal calf serum
FLAD	Failed lobuloalveolar development
HR	Hazard ratio
IgG	Immuno gamma globulin
IHC	immunohistochemistry
IP	Intraperitoneal
IRF7	interferon regulatory factor 7
MAP	Milk associated protein
MDSC	myeloid derived suppressor cells
MIN	Mammary intraepithelial neoplasia
<i>MMTV</i>	Mouse mammary tumor virus promoter
MT	Mutant
<i>Oas2</i>	oligoadenylate synthetase 2 gene
OAS2	oligoadenylate synthetase 2 protein
PBS	Phosphate buffered saline
PD-1	Programmed death receptor 1
PD-L1	Programmed death-ligand 1
PI3K	Phosphoinositide 3-kinase
PLC-gamma	Phospho lipase C
polyIC	polyinosinic–polycytidylic acid
PyMT	polyoma middle T protein

<i>PyMT</i>	polyoma middle T oncogene
RBC	Red blood cells
RIG1	retinoic acid induced gene 1
RNase-L	latent ribonuclease
RPMI	Roswell Park Medical Institute
SHC	Src homology 2 domain-containing
SRC	Rous sarcoma virus family kinases
TAZ	Tafazzin
WT	Wild type

491

492

493

Declarations

Ethics approval and consent to participate.

All mice were housed in specific pathogen-free conditions at the Australian BioResources and the Biological testing Facility of the Garvan Institute, with all animal experiments carried out according to guidelines contained within the NSW (Australia) Animal Research Act 1985, the NSW (Australia) Animal Research Regulation 2010 and the Australian code of practice for the care and use of animals for scientific purposes, (8th Edition 2013, National Health and Medical Research Council (Australia)) and approved by the Garvan/St Vincent's Animal Ethics and Experimentation Committees (approvals 14/27,16/26, 17/23, 18/36).

Consent for publication.

Not applicable.

Availability of data and materials.

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests.

The authors declare that they have no competing interests.

Funding.

This work was supported by grants from the Congress Directed Medical Research Program (BC995364 and DAMD17-01-1-0241), Cure Cancer Australia Foundation, NHMRC Australia (projects 1047149, Fellowships 545805, 481310, 1043400), the Australian Research Council Discovery Project (DP110102288), Fellowships (ECF-13-08 and ECF-16-022) from the National Breast Cancer Foundation, Banque Nationale de Paris-Paribas Australia and New Zealand, Mostyn Family Foundation, Cue Clothing Co., Estee Lauder Australia, Sutton's Motors Sydney and the RT Hall Trust.

Authors' contributions.

SRO and CJO are joint senior authors. All authors contributed to the experimentation and writing of the manuscript. All authors reviewed drafts of the manuscript and approved the final version.

Acknowledgements.

The authors acknowledge the excellent work of the staff of Australian BioResources and the Biological Testing Facility of the Garvan Institute.

Figure and Table legends

Figure 1. Effects of pregnancy on lesion histopathology.

Panel A, Milk associated protein (MAP) IHC staining of a number 4 mammary gland at day 3 post-partum from a 9-week-old dam. Inguinal region on the right-hand side, dorsal region on the left-hand side. Lesions identified and named by Lin et al.¹⁸ to be characteristic of disease progression are circled in yellow and are shown at higher magnification below. Failed lobuloalveolar development (FLAD) is indistinguishable from hyperplasia. **Panel B**, Corresponding lesion IHC staining for PyMT protein. **Panel C**, Novel histopathological features seen in the immediate post-partum period, MAP IHC of a whole 2nd and 3rd mammary glands shown in the centre panel and H&E at higher magnification of the circled features shown either side. **Panel D**, PyMT staining of metastases, **Panel E**, MAP staining of metastases.

Figure 2. Stat activation and apoptosis during tumor progression in parous mice and the effect of MT *Oas2*.

Panel A. The phosphorylation of the indicated Stat proteins is shown by specific phospho-Stat IHC and DAB staining, within the lesions defined in Fig. 1. QuPath was used to quantify overall mammary gland pStat nuclear positivity in MT and WT glands. Error bars are standard error of the mean, MT Stat1 data is not Gaussian (KS $p=0.03$) and so the Mann-Whitney U test is used to calculate the p value. Stat3 and Stat5 p values were calculated using Student's t-test. **Panel B**. Cleaved caspase 3 (CC3) IHC was used to quantify the proportion of apoptotic cells (CC3 % + cells, left hand panel), and the proportion of pixels positive for CC3 staining (CC3 % + pixels, right hand panel), in the indicated lesion subtypes abbreviated as HYP.; hyperplasia, MIN; mammary intraepithelial neoplasia, ENG.; Engorged, CAR.; carcinoma. All comparisons within lesion subtypes for CC3 between MT and WT are nonsignificant using Student's t-test.

Figure 3. Effect of MT *Oas2* and parity on primary tumor initiation and expansion.

Kaplan-Meier survival analysis for the indicated periods and endpoints, and for the indicated genotypes (MT, mutant *Oas2*; WT wild type *Oas2*), and parity status of mouse cohorts (20 per group). Mammary glands were palpated twice weekly and tumor growth was measured, as detailed in Supplementary Figure 1. Two-way Kaplan Meier

curve comparisons and p values shown in Supplementary Figure 2, n=19 MT parous, 21 WT parous, 20 MT nulliparous and 19 WT nulliparous.

Figure 4. Effect of MT *Oas2* and parity on lung metastases.

Panel A, actual tumor burden of the cohorts. All tumors were excised and weighed at autopsy, which was initiated when estimates of tumor volume calculated from calliper measurements reached 10% of body weight (BW). Abbreviations are MT, mutant *Oas2*; WT wild type *Oas2*; np, nulliparous; p, parous. Error bars are standard error of the mean and p values for the two-way comparisons indicated by the extremities of the lines were calculated using Student's t-test. Each symbol is the total tumor burden for a mouse. **Panel B**, top panel, the number of lung metastases per section counted manually using two sections per lung, 100µm apart, and bottom panel, the area of DAB+ cells stained by IHC for PyMT and quantified by QuPath, for the indicated genotypes and parity status of the mouse cohorts (20 per group). Error bars are standard error of the mean, median value is indicated by the broken bar and p values were calculated using Mann-Whitney U test. Sections without metastases (which can't be plotted on a log axis) are shown at the bottom of the figure marked "0". Each symbol is a section.

Figure 5. Effects of MT *Oas2* on T cells, neutrophils and granulocytes.

A screening of monocytes and neutrophils also known as myeloid derived suppressor cells (MDSC) was undertaken in mammary tumors. Granulocytes and neutrophils levels were quantified in the third (3MG) or fourth (4MG) and results are combined for statistical analysis. Axes show percentage of cells within the previous gate and gating strategy is shown in SFig. 4. Error bars are standard error of the mean and p values calculated by Student's t-test for the two-way comparisons indicated by the extremities of the lines. Abbreviations are MT, mutant *Oas2*; WT wild type *Oas2*; np, nulliparous; p, parous.

Figure 6. Effect of PD-L1 and MT *Oas2* on primary tumor initiation and expansion in parous mice.

Kaplan-Meier survival analysis for the indicated periods and endpoints, and for the indicated genotypes, MT, mutant *Oas2*; WT wild type *Oas2* and treatments (PD-L1 or

IgG IP twice weekly), of mouse cohorts (20 per group). All mammary glands were palpated twice weekly and tumor growth was measured by callipers. Individual tumor growth profiles are shown in as shown in Supplementary Figure 5. Two-way Kaplan-Meier comparisons and p values are shown in Supplementary Figure 6, n=8 WT PD-L1, 8 WT IgG, 14 MT PD-L1, 15 MT IgG.

Figure 7. Effect of PD-L1 and MT *Oas2* on lung metastases in parous mice at the ethical endpoint.

Panel A, actual tumor burden of the cohorts as a % of body weight (BW). All tumors were excised and weighed at autopsy, which was initiated when estimates of tumor volume calculated from calliper measurements reached 10% of body weight. Error bars are standard error of the mean and p values were calculated using Student's t-test. **Panel B**, the number of lung metastases per section, counted manually using two sections per lung 100µm apart, and the area of DAB+ cells stained by IHC for PyMT and quantified by QuPath, for the indicated genotypes and treatments (PD-L1 or IgG IP twice weekly). Mice without metastases (which can't be plotted on a log axis) are shown at the bottom of the figure marked "0". Error bars are standard error of the mean, median value is indicated by the broken bar and p values were calculated using Mann-Whitney U test for the two-way comparisons indicated by the extremities of the line. Abbreviations are MT, mutant *Oas2*; WT wild type *Oas2*

Figure 8. Effect of PD-L1 and MT *Oas2* on lung metastases in parous mice immediately following PD-L1 treatment.

Panel A, Mammary gland (MG) weight as a percentage of body weight (BW). All tumors were excised and weighed at autopsy at the completion of PD-L1 treatment, usually 2 weeks post-partum. Error bars are standard error of the mean and p values were calculated using Student's t-test. **Panel B**, the number of lung metastases per section (two sections per lung) counted manually, and the area of DAB+ cells stained by IHC for PyMT and quantified by QuPath, for the indicated genotypes and treatments (PD-L1 or IgG IP twice weekly), of mouse cohorts. Mice without metastases (which can't be plotted on a log axis) are shown at the bottom of the figure marked "0". Error bars are standard error of the mean, median value is indicated by the broken bar and p

values were calculated using Mann-Whitney U test. Abbreviations are MT, mutant *Oas2*; WT wild type *Oas2*

Supplementary Figure 1. Effect of MT *Oas2* on primary tumor expansion in parous mice.

Examples of tumor growth curves of individual mice. The left and right hand side 2nd/3rd and 4th mammary glands were palpated twice weekly and tumor growth was estimated by measurement of the major and minor axis of each gland using callipers. Y axis is placed at parity indicated on the x axis as day 0. Numbers show the total number of glands with tumors detected, the number that showed a period of no growth, and the number that showed regression at or following parity. W, wild type; M, MT; W/W, homozygous wild type; M/M, homozygous MT.

Supplementary Figure 2. Effect of MT *Oas2* on primary tumor initiation and expansion in nulliparous and parous mice.

Two-way Kaplan-Meier survival analysis for the indicated periods and endpoints, and for the indicated genotypes, WT wildtype *Oas2*, MT mutant *Oas2*, and parity status of mouse cohorts (20 per group). P values and hazard ratios (HR) calculated by the Log-Rank test using GraphPad Prism. n=19 MT parous, 21 WT parous, 20 MT nulliparous and 19 WT nulliparous.

Supplementary Figure 3. Effects of MT *Oas2* on T cells in parous mice.

A screening of various T-cell parameters was undertaken in mammary tumors, lymph nodes, spleen and thymus. Error bars are standard error of the mean and p values calculated by Student's t-test (all non significant). Axes represent % of total cells passing the previous gate. Genotypes, WT/WT homozygous wildtype *Oas2*, MT/MT homozygous mutant *Oas2*.

Supplementary Figure 4. Flowcytometry gating strategy for monocytes and neutrophils known as myeloid derived suppressor cells.

Series of gates used to quantify monocytes and neutrophils using flow cytometry.

Supplementary Figure 5. Effect of PD-L1 and MT *Oas2* on primary tumor initiation and expansion in parous mice.

Examples of tumor growth curves of individual mice. The 2nd/3rd and 4th mammary glands were palpated twice weekly and tumor growth was estimated by measurement of the major and minor axis of individual tumors using callipers. Y axis is placed at the day of tumor detection on the x axis as day 0. Black diamonds show a treatment with IP IgG or PD-L1 antibodies and red diamonds indicate parity. WT=wild type, MT=MT *Oas2* MT/MT = homozygous MT *Oas2*.

Supplementary Figure 6. Effect of PD-L1 and MT *Oas2* on primary tumor initiation and expansion in parous mice.

Two-way Kaplan-Meier survival analysis for the indicated periods and endpoints, and for the indicated genotypes and treatments (PD-L1 or IgG IP), of mouse cohorts. P values and hazard ratios (HR) calculated by the Log-Rank test using GraphPad Prism. n=8 WT PD-L1, 8 WT IgG, 14 MT PD-L1, 15 MT IgG.

Supplementary Table 1. Antibodies, concentration and antigen retrieval conditions for immunohistochemistry.

All reagents were from Leica BOND or DAKO for automated or manual IHC (as specified). Visualization of antigen: antibody complexes was performed using the DAB+ liquid Substrate chromogen system (K3467).

Antigen	Primary Antibody Supplier, Cat #	Primary Ab Concentration & Incubation	Detection System	Antigen Retrieval	Secondary Ab (cat#)
Polyoma Virus, Middle T Antigen	Novus Biologicals, NB100-2749	1:300, 60min	BOND Polymer Refine (DS9800)	HIER 30min, ER2 (EDTA pH9) 100°C	Vector Labs Rabbit anti-Rat (BA-4001-.5) 1:200
Phospho-Stat1 (Y701)	Cell Signalling, 9167	1:400, 60min	BOND Polymer Refine (DS9800)	HIER 30min, ER2 (EDTA pH9) 100°C	BOND Rab Polymer only

Phospho-Stat3 (Y705)	Cell Signalling, 9145	1:400, 60min	BOND Polymer Refine (DS9800)	HIER 30min, ER2 (EDTA pH9) 100°C	BOND Rab Polymer only
Phospho-Stat5 (Y964)	Cell Signalling, 9351	1:400, 60min	BOND Polymer Refine (DS9800)	HIER 30min, ER2 (EDTA pH9) 100°C	BOND Rab Polymer only
Cleaved Caspase 3	Cell Signalling, 9664	1:800, 60min	BOND Polymer Refine (DS9800)	HIER 20min, ER2 (EDTA pH9) 100°C	BOND Rab Polymer only
CD8 α	Cell Signalling, 98941	1:200, 30min	BOND Polymer Refine (DS9800)	HIER 20min, ER2 (EDTA pH9) 100°C	BOND Rab Polymer only
Milk Associated Protein	Accurate Chemical & Scientific Co., YNRMTM	1:12,000, 60min	DAKO manual IHC	DAKO pH6 S1699, 100°C water bath, 20min	Envision Rab (K4009)
CD45	BD Pharmigen, BD553077	1:200, 60min	DAKO & Vector Labs manual IHC	DAKO pH6 S1699, 100°C water bath, 20min	VECTASTAIN Elite ABC-HRP (PK-6100)

Supplementary Table 2. Antibodies used for flow cytometry.

Panel name, antibody name by antigen recognised and conjugated fluorochrome, the antibody supplier and catalogue number and final diluted concentration for each is shown.

Antibody Panel	Antigen & Fluorochrome	Supplier, Cat #	Antibody Concentration
B & T Cell Panel	CD44 FITC	BD Biosciences, 561859	1/300
	CD366 (Tim-3) PE	BioLegend, 119704	1/200

	CD3 PerCP-Cy5.5	BioLegend, 100217	1/200
	CD279 (PD-1) PE-Cy7	eBioscience, 25-9985-82	1/400
	CD25 APC	BD Biosciences, 557192	1/100
	TCR β chain APC -Cy7	BioLegend, 109220	1/400
	CD44 Pacific blue	BioLegend, 103020	1/300
	Zombie Aqua™ Fixable Viability Kit	BioLegend, 423101	1/500
	CD62L BV605	BioLegend, 104438	1/800
	CD45R (B220) BV786	BD Biosciences, 563894	1/300
	CD8a BUV395	BD Biosciences, 563786	1/300
	CD4 BUV737	BD Biosciences, 564306	1/300
T Cell Panel	CD28 FITC	BioLegend, 122007	1/200
	CD25 PE	eBioscience, 12-0251-83	1/200
	CD62L PerCP-Cy5.5	BD Biosciences, 560513	1/200
	CD279 (PD-1) PE-Cy7	eBioscience, 25-9985-82	1/400
	CD152 (CTLA4) APC	eBioscience, 17-1522-82	1/100
	CD278 ICOS APC-Cy7 (e780)	Australian Bioresearch, 313529	1/400
	Foxp3 eFLour450	eBioscience, 48-5773-80	1/100
	Zombie Aqua™ Fixable Viability Kit	BioLegend, 423101	1/500
	CD44 BV605	BD Biosciences, 563058	1/200
	TCR β Biotin & BV786 Streptavidin	BD Biosciences, 553169 & 563858	1/300 (Primary Ab)
	CD8a BUV395	BD Biosciences, 563786	1/300
	CD4 BUV737	BD Biosciences, 564306	1/300
Myeloid Panel	Gr1 PE	BioLegend, 108408	1/200

	Ly6C PerCP-Cy5.5	BioLegend, 128011	1/200
	CD45 PE-Cy7	BioLegend, 103114	1/200
	F4/80 APC	BioLegend, 123116	1/200
	CD11b APC e780	eBioscience, 47- 0122-82	1/200
	Zombie Aqua™ Fixable Viability Kit	BioLegend, 423101	1/500
	Ly6G BV711	BD Biosciences, 563979	1/200

686
687

References.

1. Parker, B.S., Rautela, J. & Hertzog, P.J. Antitumour actions of interferons: implications for cancer therapy. *Nat Rev Cancer* **16**, 131-144 (2016).
2. Benci, J.L. *et al.* Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. *Cell* **178**, 933-948 e914 (2019).
3. Borden, E.C. Interferons alpha and beta in cancer: therapeutic opportunities from new insights. *Nat Rev Drug Discov* **18**, 219-234 (2019).
4. Kyi, C. *et al.* Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research* **24**, 4937-4948 (2018).
5. Nagato, T., Lee, Y.R., Harabuchi, Y. & Celis, E. Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research* **20**, 1223-1234 (2014).
6. Silverman, R.H. Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response. *Journal of virology* **81**, 12720-12729 (2007).
7. Donovan, J., Dufner, M. & Korennykh, A. Structural basis for cytosolic double-stranded RNA surveillance by human oligoadenylate synthetase 1. *Proceedings of the National Academy of Sciences of the United States of America* **110**, 1652-1657 (2013).
8. Chakrabarti, A., Jha, B.K. & Silverman, R.H. New insights into the role of RNase L in innate immunity. *Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research* **31**, 49-57 (2011).
9. Madsen, B.E. *et al.* Germline mutation in RNASEL predicts increased risk of head and neck, uterine cervix and breast cancer. *PloS one* **3**, e2492 (2008).
10. Banerjee, S. *et al.* OAS-RNase L innate immune pathway mediates the cytotoxicity of a DNA-demethylating drug. *Proceedings of the National Academy of Sciences of the United States of America* **116**, 5071-5076 (2019).
11. Fesinmeyer, M.D., Kwon, E.M., Fu, R., Ostrander, E.A. & Stanford, J.L. Genetic variation in RNASEL and risk for prostate cancer in a population-based case-control study. *Prostate* **71**, 1538-1547 (2011).
12. Meyer, M.S. *et al.* Genetic variation in RNASEL associated with prostate cancer risk and progression. *Carcinogenesis* **31**, 1597-1603 (2010).
13. Nguyen-Dumont, T. *et al.* Is RNASEL:p.Glu265* a modifier of early-onset breast cancer risk for carriers of high-risk mutations? *BMC cancer* **18**, 165 (2018).
14. Yin, H., Jiang, Z., Wang, S. & Zhang, P. IFN-gamma restores the impaired function of RNase L and induces mitochondria-mediated apoptosis in lung cancer. *Cell Death Dis* **10**, 642 (2019).

- 735 15. Oakes, S.R. *et al.* A mutation in the viral sensor 2'-5'-oligoadenylate
736 synthetase 2 causes failure of lactation. *PLoS genetics* **13**, e1007072
737 (2017).
- 738 16. Guy, C.T., Cardiff, R.D. & Muller, W.J. Induction of mammary tumors by
739 expression of polyomavirus middle T oncogene: a transgenic mouse
740 model for metastatic disease. *Mol Cell Biol* **12**, 954-961 (1992).
- 741 17. Fluck, M.M. & Schaffhausen, B.S. Lessons in signaling and tumorigenesis
742 from polyomavirus middle T antigen. *Microbiol Mol Biol Rev* **73**, 542-563,
743 Table of Contents (2009).
- 744 18. Lin, E.Y. *et al.* Progression to malignancy in the polyoma middle T
745 oncoprotein mouse breast cancer model provides a reliable model for
746 human diseases. *The American journal of pathology* **163**, 2113-2126
747 (2003).
- 748 19. Allen, E. *et al.* Combined antiangiogenic and anti-PD-L1 therapy
749 stimulates tumor immunity through HEV formation. *Sci Transl Med* **9**
750 (2017).
- 751 20. Messenheimer, D.J. *et al.* Timing of PD-1 Blockade Is Critical to Effective
752 Combination Immunotherapy with Anti-OX40. *Clinical cancer research :
753 an official journal of the American Association for Cancer Research* **23**,
754 6165-6177 (2017).
- 755 21. Lin, E.Y. *et al.* Vascular endothelial growth factor restores delayed tumor
756 progression in tumors depleted of macrophages. *Mol Oncol* **1**, 288-302
757 (2007).
- 758 22. Lin, E.Y., Nguyen, A.V., Russell, R.G. & Pollard, J.W. Colony-stimulating
759 factor 1 promotes progression of mammary tumors to malignancy. *J Exp
760 Med* **193**, 727-740 (2001).
- 761 23. Gallego-Ortega, D. *et al.* ELF5 drives lung metastasis in luminal breast
762 cancer through recruitment of Gr1+ CD11b+ myeloid-derived suppressor
763 cells. *PLoS biology* **13**, e1002330 (2015).
- 764 24. Veglia, F., Sanseviero, E. & Gabrilovich, D.I. Myeloid-derived suppressor
765 cells in the era of increasing myeloid cell diversity. *Nature reviews.
766 Immunology* (2021).
- 767 25. Bankhead, P. *et al.* QuPath: Open source software for digital pathology
768 image analysis. *Sci Rep* **7**, 16878 (2017).
- 769 26. Bradley, L.M., Atkins, G.G. & Swain, S.L. Long-term CD4+ memory T cells
770 from the spleen lack MEL-14, the lymph node homing receptor. *Journal of
771 immunology* **148**, 324-331 (1992).
- 772 27. MacDonald, H.R., Budd, R.C. & Cerottini, J.C. Pgp-1 (Ly 24) as a marker of
773 murine memory T lymphocytes. *Curr Top Microbiol Immunol* **159**, 97-109
774 (1990).
- 775 28. Rose, S., Misharin, A. & Perlman, H. A novel Ly6C/Ly6G-based strategy to
776 analyze the mouse splenic myeloid compartment. *Cytometry A* **81**, 343-
777 350 (2012).
- 778 29. Daling, J.R., Malone, K.E., Doody, D.R., Anderson, B.O. & Porter, P.L. The
779 relation of reproductive factors to mortality from breast cancer. *Cancer
780 Epidemiol Biomarkers Prev* **11**, 235-241 (2002).
- 781 30. Whiteman, M.K. *et al.* Reproductive history and mortality after breast
782 cancer diagnosis. *Obstet Gynecol* **104**, 146-154 (2004).

- 783 31. Albrektsen, G., Heuch, I., Hansen, S. & Kvale, G. Breast cancer risk by age at
784 birth, time since birth and time intervals between births: exploring
785 interaction effects. *Br J Cancer* **92**, 167-175 (2005).
- 786 32. Colditz, G.A. & Rosner, B. Cumulative risk of breast cancer to age 70 years
787 according to risk factor status: data from the Nurses' Health Study.
788 *American journal of epidemiology* **152**, 950-964 (2000).
- 789 33. Mathews, T. & Hamilton, B. Mean age of mothers is on the rise: United
790 States, 2000-2014. *NCHS Data Brief* **No 232** (2016).
- 791 34. Studies, A.I.o.F. Births in Australia-Age of new mothers. (2018).
- 792 35. Lee, G.E., Mayer, E.L. & Partridge, A. Prognosis of pregnancy-associated
793 breast cancer. *Breast cancer research and treatment* **163**, 417-421 (2017).
- 794 36. DeSantis, C.E. *et al.* International Variation in Female Breast Cancer
795 Incidence and Mortality Rates. *Cancer Epidemiol Biomarkers Prev* **24**,
796 1495-1506 (2015).
- 797 37. Collaborative Group on Hormonal Factors in Breast, C. Breast cancer and
798 breastfeeding: collaborative reanalysis of individual data from 47
799 epidemiological studies in 30 countries, including 50302 women with
800 breast cancer and 96973 women without the disease. *Lancet* **360**, 187-
801 195 (2002).
- 802 38. Valdes-Mora, F. *et al.* Single-cell RNAseq uncovers involution mimicry as
803 an aberrant development pathway during breast cancer metastasis. *Cell*
804 *Reports* **35**, 108945 (2021).
- 805 39. Lee, H.J. *et al.* Lineage specific methylation of the Elf5 promoter in
806 mammary epithelial cells. *Stem Cells* **29**, 1611-1619 (2011).
- 807

A. Phospho-Stat IHC

B. Cleaved caspase 3 IHC

A. Age at Tumor Detection

B. Time from Detection to Ethical Endpoint

C. Age at Ethical Endpoint

A. Tumour % Body Weight at Ethical Endpoint

B. Metastases

A. Age at Tumor Detection

B. Time from Detection to Ethical Endpoint

C. Age at Ethical Endpoint

A. Tumour % Body Weight at Ethical Endpoint

B. Metastases

A. Mammary Gland % Body Weight at d15pp

B. Metastases

Ho et al. Supplementary Figure 1.

Ho et al. Supplementary Figure 3.

Gating strategy monocytes and neutrophils (MDSC)